StockNews.AI
NAVB
StockNews.AI
141 days

Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets

1. NAVB extends its Section 382 Rights Agreement to safeguard NOLs until 2027.

2m saved
Insight
Article

FAQ

Why Bullish?

Extending the rights agreement protects NAVB's tax assets, potentially improving financial stability. Past examples show similar actions often positively influence company valuations.

How important is it?

Protecting NOLs is crucial for NAVB, potentially enhancing its attractiveness to investors and supporting capital raises.

Why Long Term?

The extended rights plan will support NAVB's fiscal health over the next several years, enhancing long-term investor confidence.

Related Companies

AMGNMRKABBV
COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”) today announced that its Board of Directors has elected to extend the Company's Section 382 Rights Agreement (the “Section 382 Rights Plan”). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027. The Section 382 Rights Plan is designed to safeguard Navidea's ability to utilize its net operating loss carryforwards (“NOLs”) and other ta.

Related News